Discover what VCs really want from biotech startups and how founders can strategically position themselves for investment success. Plus, tips for building trust, reducing risk, and creating long-term value.

Biotech’s AI buzz is fading—but now comes the real work. Here’s a 90-day action plan to turn hype into operational success.

Biotech is still chasing AI dreams while bleeding cash. It's time to rethink how we integrate AI—with clarity, purpose, and ROI in mind.

Everyone is betting on AI to revolutionize drug development. But what if it's more smoke than substance? Here's what biotech insiders need to know before pouring more money into the hype.

Explore the top challenges facing the biotech industry in 2025 and discover strategic solutions to navigate funding constraints, regulatory shifts, and workforce dynamics.

Biotech startup funding is collapsing under outdated metrics, risk-averse investors, and inflated promises. Here's how to rebuild smarter.

Biotech investors are still chasing crowded, overhyped pipelines—while the real opportunities lie in scalable, underfunded disease areas and trial innovation. This article breaks down where VCs and startups should focus to win funding in today’s clinical development landscape. Stop pitching potential. Start delivering value at scale.

Cancer trials dominate biotech R&D, but are we chasing real cures or inflating a therapeutic bubble? This article breaks down why oncology’s outsized investment may be delivering less impact than we think—and what that means for the future of clinical development.

A provocative look into the bloated oncology clinical trial landscape. Is the industry prioritizing profit over progress—and what does that mean for investors, CROs, and patients?

AI is the hot topic in biotech, but is it really the game-changer everyone claims it is? In this article, I break down why relying solely on AI might put your biotech startup at risk—and how to harness its power without falling for the hype. Ready to learn how AI can work for you? Let’s dive in!

Everyone’s pitching “AI-powered” drug discovery in biotech—but here’s the truth no one wants to say out loud: AI won’t save your startup if you don’t have a real regulatory or data strategy.
In my latest article, I break down why funders are pulling back, and what smart teams are doing differently to stand out in 2025.

Discover the top 5 highest-risk areas in biotech and clinical trials in 2025—from protocol feasibility failures to regulatory landmines with AI and RWD. Learn how leading biotech teams are navigating these challenges with smarter strategy, patient-centered design, and operational resilience.

The top biotech trends for 2025 are here—AI, patient-centered design, and trial decentralization. But what’s next? Learn how leading biotech teams are turning trends into strategy, funding, and FDA-ready trials.

Explore the top 3 biotech trends in 2025, including AI-powered trial strategy, operational readiness, and milestone-based capital. A must-read for investors, CROs, and startup founders navigating the evolving life sciences landscape.

Discover the biggest issue stalling biotech startups: great science with no executable strategy. Learn how founders can align their trials, timelines, and teams to secure funding and move forward faster.

AI isn’t just transforming biotech—it’s redefining how we run clinical trials. From smarter site selection to FDA-aligned adaptive protocols, the future is already here. Read my latest newsletter to see how researchers, regulators, and investors are navigating the AI-powered shift.

Biotech startups face massive pressure — from funding gaps to regulatory uncertainty and trial design missteps. This article breaks down the biggest fears founders face and offers practical strategies to stay ahead, build smarter, and avoid costly mistakes.

FDA guidance updates aren’t just regulatory noise—they can shift your entire startup strategy. From decentralized trials to AI oversight, recent changes have major implications for INDs, clinical design, and early engagement. Here’s what every biotech founder needs to know

Explore the implications of the FDA’s updated conditional approval process and how biotech companies can adapt their development strategies to stay competitive.

The FDA isn't standing still—and neither should your biotech strategy. From accelerated approval adjustments to updated guidance on decentralized trials and pre-IND interactions, recent changes are sending a clear signal: biotech companies must be sharper, faster, and more aligned than ever before.
Here’s what you need to know—and how to prepare.